Am J Psychiatry 161:975-984, June 2004
© 2004 American Psychiatric Association
Placebo-Controlled Evaluation of Four Novel Compounds for the Treatment of Schizophrenia and Schizoaffective Disorder
Herbert Y. Meltzer, M.D.,
Lisa Arvanitis, M.D.,
Deborah Bauer, M.S., and
Werner Rein, M.D. Meta-Trial Study Group
OBJECTIVE: Four studies using identical protocols evaluated the safety and efficacy of four novel, evidence-based targets for antipsychotic agents: a neurokinin (NK3) antagonist (SR142801), a serotonin 2A/2C (5-HT2A/2C) antagonist (SR46349B), a central cannabinoid (CB1) antagonist (SR141716), and a neurotensin (NTS1) antagonist (SR48692). METHOD: Adults with schizophrenia or schizoaffective disorder (N=481) were randomly assigned in a 3:1:1 ratio to receive fixed doses of investigational drug, placebo, or haloperidol for 6 weeks. Primary efficacy variables included changes from baseline in total score on the Positive and Negative Syndrome Scale, severity of illness score on the Clinical Global Impression (CGI), and total score and psychosis cluster score on the Brief Psychiatric Rating Scale (BPRS). RESULTS: Significantly greater improvement in all primary efficacy variables was seen in the group receiving haloperidol than in the group receiving placebo at 6 weeks (endpoint analyses), indicating the validity of the study. The group receiving the NK3 antagonist showed significantly greater improvement over baseline than the group receiving placebo as measured by Positive and Negative Syndrome Scale total score, CGI severity of illness score, and BPRS psychosis cluster score. Reductions in the Positive and Negative Syndrome Scale total and negative scores in the group receiving the 5-HT2A/2C antagonist were significantly larger than those in the group receiving placebo. The improvements in psychopathology produced by the NK3 and 5-HT2A/2C antagonists were smaller than those produced by haloperidol, although the response to the NK3 antagonist was positively correlated with plasma levels. The groups receiving the CB1 and NTS1 antagonists did not differ from the group receiving placebo on any outcome measure. All investigational drugs were well tolerated. CONCLUSIONS: The novel design used in this study permitted the use of a smaller number of patients receiving placebo to test the efficacy of the four novel compounds. The NK3 and 5-HT2A/2C antagonists showed evidence of efficacy in the treatment of schizophrenia and schizoaffective disorder. Study limitations preclude a definitive conclusion on the efficacy of CB1 and NTS1 antagonists in the treatment of schizophrenia. Further study of these two promising nondopaminergic mechanisms to treat schizophrenia and schizoaffective disorder appears indicated.
This article has been cited by other articles:
|
|
|
|
 
J. Rabinowitz, S. Z. Levine, O. Barkai, and O. Davidov
Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design Features
Schizophr Bull,
July 1, 2009;
35(4):
775 - 788.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. I. Abbas, P. N. Yadav, W.-D. Yao, M. I. Arbuckle, S. G. N. Grant, M. G. Caron, and B. L. Roth
PSD-95 Is Essential for Hallucinogen and Atypical Antipsychotic Drug Actions at Serotonin Receptors
J. Neurosci.,
June 3, 2009;
29(22):
7124 - 7136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Ardayfio, M. J. Benvenga, S. F. Chaney, P. L. Love, J. Catlow, S. P. Swanson, and G. J. Marek
The 5-Hydroxytryptamine2A Receptor Antagonist R-(+)-{alpha}-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl-4-piperidinemethanol (M100907) Attenuates Impulsivity after Both Drug-Induced Disruption (Dizocilpine) and Enhancement (Antidepressant Drugs) of Differential-Reinforcement-of-Low-Rate 72-s Behavior in the Rat
J. Pharmacol. Exp. Ther.,
December 1, 2008;
327(3):
891 - 897.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Malherbe, C. Bissantz, A. Marcuz, C. Kratzeisen, M.-T. Zenner, J. G. Wettstein, H. Ratni, C. Riemer, and W. Spooren
Me-Talnetant and Osanetant Interact within Overlapping but Not Identical Binding Pockets in the Human Tachykinin Neurokinin 3 Receptor Transmembrane Domains
Mol. Pharmacol.,
June 1, 2008;
73(6):
1736 - 1750.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Pacher, S. Batkai, and G. Kunos
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pharmacol. Rev.,
September 1, 2006;
58(3):
389 - 462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. W. Zuardi, J. E. C. Hallak, S. M. Dursun, S. L. Morais, R. F. Sanches, R. E. Musty, and J. A. S. Crippa
Cannabidiol monotherapy for treatment-resistant schizophrenia
J Psychopharmacol,
September 1, 2006;
20(5):
683 - 686.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. V. Madsen, L. Peacock, T. Werge, and M. B. Andersen
Effects of the cannabinoid CB1 receptor agonist CP55,940 and antagonist SR141716A on d-amphetamine-induced behaviours in Cebusmonkeys
J Psychopharmacol,
September 1, 2006;
20(5):
622 - 628.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. M. Gadde and D. B. Allison
Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks
Circulation,
August 29, 2006;
114(9):
974 - 984.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Laviolette and A. A. Grace
Cannabinoids Potentiate Emotional Learning Plasticity in Neurons of the Medial Prefrontal Cortex through Basolateral Amygdala Inputs.
J. Neurosci.,
June 14, 2006;
26(24):
6458 - 6468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Vanover, D. M. Weiner, M. Makhay, I. Veinbergs, L. R. Gardell, J. Lameh, A. L. Del Tredici, F. Piu, H. H. Schiffer, T. R. Ott, et al.
Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2R,3R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse Agonist
J. Pharmacol. Exp. Ther.,
May 1, 2006;
317(2):
910 - 918.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Pagotto, G. Marsicano, D. Cota, B. Lutz, and R. Pasquali
The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance
Endocr. Rev.,
February 1, 2006;
27(1):
73 - 100.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. I. G. Holt
Obesity - an epidemic of the twenty-first century: an update for psychiatrists
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
6 - 15.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. RICHELSON, P. A. FREDRICKSON, and M. M. BOULES
Neurotensin Receptor Agonists and Antagonists for Schizophrenia
Am J Psychiatry,
March 1, 2005;
162(3):
633 - 634.
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2004
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
